ArticleBMJ open respiratory research2026
Analysis of clinical features of AECOPD at different altitudes and GOLD stages in high-altitude regions.
Article in BMJ open respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Validation of SpOAdvances in respiratory medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyse the clinical features of AECOPD (acute exacerbation of chronic obstructive pulmonary disease) at different altitudes and GOLD (global initiative of chronic obstructive lung disease) stages in high-altitude regions.
methodThis was a retrospective cross-sectional study. Patients diagnosed with AECOPD through pulmonary function tests and hospitalised in People's Hospital of the Tibet Autonomous Region from September 2018 to March 2024 were included. Patients were divided into three groups according to their native residential altitude prior to onset: low-altitude group (169 cases, 2700-3700 m), mid-altitude group (77 cases, 3700-4000 m) and high-altitude group (97 cases, 4000-4800 m). Patients were also classified into three groups according to their FEV1%pred in pulmonary function test on admission: mild (91 cases, FEV1%pred ≥80%), moderate (171 cases, 50%≤FEV1%pred <80%) and severe/very severe (81 cases, FEV1%pred <50%).
result(1) Altitude comparison: the mid-altitude group showed lower values for age (66.49±8.13 years), hospital length of stay (9.79±3.20 days) and time since diagnosis (1.89±1.73 years) compared with the low-altitude group. On the other hand, the mid-altitude group showed higher SPO
conclusionIn high-altitude regions, as the altitude increases, body mass index, the proportion of male patients, rate of emphysema and pulmonary hypertension become more prominent in AECOPD patients. Higher GOLD stages are associated with longer hospital stays, higher smoking indices and greater prevalence of emphysema, pulmonary fibrosis, pulmonary hypertension and cor pulmonale. Lower SPO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.